EnteroBiotix Concludes Recruitment for P-II Trial of EBX-102-02 in IBS
Shots:
- EnteroBiotix reported the completion of recruitment in its P-II (TrIuMPH) trial evaluating the safety, tolerability, and efficacy of EBX-102-02 in IBS
- The P-II trial recruited 122 individuals (62 with constipation-predominant IBS & 60 with diarrhoea-predominant IBS), dosed with EBX-102-02 vs PBO and followed up for 6wks. at two clinical sites in the UK. Topline data anticipated in Q1'25
- EBX-102-02 (capsule) is a microbiome drug candidate, which also showed positive results in a P-Ib trial of its full-spectrum product EBX-102 in liver cirrhosis
Ref: EnteroBiotix | Image: EnteroBiotix
Related News:- EnteroBiotix Commences the P-II Clinical Evaluation of EBX-102-02 for the Treatment of Irritable Bowel Syndrome (IBS)
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
An avid reader and a dedicated learner, Prince works as a Content Writer at PharmaShots. Prince possesses an exceptional quality of breaking down the barriers of words by simplifying the terms in digestible chunks to make content readable and comprehensible. Prince likes to read books and loves to spend his free time learning and upskilling himself.
